Dr. Bai Xiang – Professor

Bai Xiang

Professor, Supervisor of Doctorate Candidates, Supervisor of Master's Candidates

Director, Department of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University,

050017, Shijiazhuang, Hebei, CHINA

Tel: 86-311-8626-5591

E-mail: baixiang@hebmu.edu.cn 

Education

Ph.D. (Pharmaceutics), Peking University (China), 2013

M.S. (Pharmaceutics), Shenyang Pharmaceutical University (China), 2005

Employment 

Visiting Professor, University of California, Davis（2019-2020）

Professor, Dept. Pharmaceutics, Hebei Medical University（2018-present）

Research interests

Nanoparticle-based targeted drug/gene delivery System for treatment of various types of tumor and diseases of the nervous system

Representative Publications

1. Xu H, Liu B, Xiao Z, Zhou ML, Ge L, Jia F, Liu YL, Jin HS, Zhu XL, Gao J, Akhtar J, Xiang B*, Tan K*, Wang GY*. Computational and Experimental Studies Reveal That Thymoquinone Blocks the Entry of Coronaviruses Into In Vitro Cells., Infect Dis Ther, 2021, 10(1): 483-494. DOI: 10.1007/s40121-021-00400-2.

2. Xiang B*, Cao DY. Dual-modified siRNA-loaded liposomes for prostate cancer therapy. In: Lu WL, Qi XR. (eds) Liposome-based drug delivery systems. Biomaterial engineering. Springer, Berlin, Heidelberg, 2018.6.30. DOI: 10.1007/978-3-662-49231-4_19-1.

3. Xiang B*, Cao DY. Preparation of drug liposomes by thin-film hydration and homogenization. In: Lu WL, Qi XR. (eds) Liposome-based drug delivery systems. Biomaterial engineering. Springer, Berlin, Heidelberg, 2017.12.4. DOI: 10.1007/978-3-662-49231-4_2-1.

4. Xiang B#, Jia XL#, Qi JL, Yang LP, Sun WH, Yan X, Yang SK, Cao DY*, Du Q*, Qi XR. Enhancing siRNA-based cancer therapy using a new pH-responsive activatable cell-penetrating peptide-modified liposomal system, Int J Nanomedicine, 2017, 12: 2385-2405. PMID: 28405163.

5. Yang SK, Yan X, Sun WH, Du Q, Xiang B*, Cao DY*, Qi XR. Activatable cell-penetrating peptides: a potential activatable modality for diseases diagnosis and therapy, Acta Pharm Sin, 2016, 51(4):529-535. PMID: 33532909.

6. He F, Cao L, Zhang XJ, Xiang B*, Cao DY*, Qi XR. The application of enzyme-sensitive activatable cell-penetrating peptides to targeted delivery system, Acta Pharm Sin, 2015, 50(2):141-147. PMID: 29859520.

7. Yang ZZ, Xiang B, Dong DW, Wang ZZ, Li JQ, Qi XR*. Dual receptor-specific peptides modified liposomes as VEGF siRNA vector for tumor-targeting therapy, Curr Gene Ther, 2014, 14(4): 289-299. PMID: 25975019.

8. Xiang B, Dong DW, Shi NQ, Gao W, Yang ZZ, Cui Y, Cao DY, Qi XR*. PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer, Biomaterials, 2013, 34(28): 6976-6991. PMID: 23777916.

9. Shi NQ*, Qi XR*, Xiang B, Zhang Y. A survey on "Trojan Horse" peptides: opportunities, issues and controlled entry to "Troy", J Control Release, 2014, 194:53-70. PMID: 25151981.

10. Dong DW, Xiang B, Gao W, Yang ZZ, Li JQ, Qi XR*. pH-responsive complexes using prefunctionalized polymers for synchronous delivery of doxorubicin and siRNA to cancer cells, Biomaterials, 2013, 34(20): 4849-4859. PMID: 23541420.

11. Gao W, Xiang B, Meng TT, Liu F, Qi XR*. Chemotherapeutic drug delivery to cancer cells using a combination of folate targeting and tumor microenvironment-sensitive polypeptides, Biomaterials, 2013, 34(16): 4137-4149. PMID: 23453200.

12. Tong SW, Xiang B, Dong DW, Qi XR*. Enhanced antitumor efficacy and decreased toxicity by self-associated docetaxel in phospholipid-based micelles, Int J Pharm, 2012, 43(1-2): 413-419. PMID: 22698861.